Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-Resistant Fallopian Tube Carcinoma”

164 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 164 results

Testing effectiveness (Phase 2)Study completedNCT03776812
What this trial is testing

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma
Corcept Therapeutics 178
Early research (Phase 1)Study completedNCT03030287
What this trial is testing

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Who this might be right for
Cancer OvariesCancer PeritonealCancer, Fallopian Tube
OncoMed Pharmaceuticals, Inc. 44
Large-scale testing (Phase 3)Active Not RecruitingNCT02839707
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Seromucinous Carcinoma+16 more
National Cancer Institute (NCI) 444
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Not applicableEnded earlyNCT03412630
What this trial is testing

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
ECOG-ACRIN Cancer Research Group 1
Testing effectiveness (Phase 2)Study completedNCT03657043
What this trial is testing

Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Seagen Inc. 98
Testing effectiveness (Phase 2)Looking for participantsNCT04055649
What this trial is testing

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Who this might be right for
Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma+7 more
Ira Winer 62
Testing effectiveness (Phase 2)Ended earlyNCT04019288
What this trial is testing

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 12
Testing effectiveness (Phase 2)Looking for participantsNCT05465941
What this trial is testing

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
Mayo Clinic 43
Testing effectiveness (Phase 2)Study completedNCT03161132
What this trial is testing

Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin

Who this might be right for
Advanced Ovarian Cancer
Grupo Español de Investigación en Cáncer de Ovario 32
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Large-scale testing (Phase 3)Looking for participantsNCT05281471
What this trial is testing

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more
Genelux Corporation 186
Early research (Phase 1)Active Not RecruitingNCT05617755
What this trial is testing

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Who this might be right for
Carcinoma, Ovarian EpithelialOvarian NeoplasmsFallopian Tube Neoplasms+6 more
Arsenal Biosciences, Inc. 19
Testing effectiveness (Phase 2)WithdrawnNCT05672095
What this trial is testing

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
City of Hope Medical Center
Large-scale testing (Phase 3)Ended earlyNCT05092360
What this trial is testing

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Who this might be right for
Platinum-resistant Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Mural Oncology, Inc 456
Testing effectiveness (Phase 2)UnknownNCT04376073
What this trial is testing

Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Jihong Liu 40
Testing effectiveness (Phase 2)Looking for participantsNCT06906341
What this trial is testing

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms+1 more
Corcept Therapeutics 270
Early research (Phase 1)Study completedNCT05483933
What this trial is testing

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Who this might be right for
Platinum-resistant Ovarian CancerFallopian Tube CancerEpithelial Ovarian Cancer+4 more
Shattuck Labs, Inc. 86
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Testing effectiveness (Phase 2)Ended earlyNCT02012192
What this trial is testing

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Medical University Innsbruck 133
Load More Results